Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
Schistosomiasis Vaccine
About Schistosomiasis Vaccine
Schistosomiasis vaccines target Schistosoma parasites, which infect more than 200 million people. Schistosomiasis causes chronic illness, organ damage, and impaired growth. The disease is transmitted through contaminated freshwater in tropical regions. The Bilhvax vaccine candidate, developed at the Pasteur Institute in Lille, uses a recombinant protein. Clinical trials showed safety and immunogenicity but a Phase 3 trial did not demonstrate efficacy. Sm14, a Brazilian vaccine candidate, has been tested in early clinical trials. Schistosomiasis control currently relies on the drug praziquantel and snail control. The WHO targets elimination of schistosomiasis as a public health problem by 2030. A vaccine would be transformative, particularly in areas with repeated reinfection. Development is hampered by limited commercial incentives for a disease of poverty.
Related Entries
Malaria Vaccine
The malaria vaccine RTS,S or Mosquirix, developed by GlaxoSmithKline over 30 years, was recommended ...
Dengue Vaccine
Dengvaxia, the first dengue vaccine, was developed by Sanofi Pasteur and licensed in Mexico in Decem...
Chikungunya Vaccine
IXCHIQ, developed by Valneva, became the first chikungunya vaccine approved by the FDA in November 2...
Leishmaniasis Vaccine
Leishmaniasis vaccines have been in development for decades. Leishmaniasis is a parasitic disease tr...